P2.07. Stage 3 NSCLC Patients Progressing After Concurrent Chemo-Radiotherapy and Durvalumab- is There a Role for Another IO? - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Jair Bar
Meta Tag
Speaker Jair Bar
Topic Metastatic NSCLC: Immunotherapy - Retrospective
WCLC 2023
unresectable stage III NSCLC
non-small cell lung cancer
immune checkpoint inhibitor
metastatic disease
adenocarcinoma histology
overall survival
progression-free survival
Powered By